Search Results - "Fasching, Peter"

Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement by Nabieva, Naiba, Fasching, Peter

“…Purpose of review: Due to the findings of current studies and the approval of novel substances for the therapy of hormone-receptor-positive breast cancer…”
Get full text

CDK4/6 Inhibitors-Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer by Nabieva, Naiba, Fasching, Peter A

“…Tamoxifen and aromatase inhibitors can be considered as some of the first targeted therapies. For the past 30 years, they were the endocrine treatment standard…”
Get full text

PROTAC drugs in cancer care by Fasching, Peter A

Get full text

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 by Slamon, Dennis J, Neven, Patrick, Chia, Stephen, Fasching, Peter A, De Laurentiis, Michelino, Im, Seock-Ah, Petrakova, Katarina, Bianchi, Giulia Val, Esteva, Francisco J, Martín, Miguel, Nusch, Arnd, Sonke, Gabe S, De la Cruz-Merino, Luis, Beck, J Thaddeus, Pivot, Xavier, Vidam, Gena, Wang, Yingbo, Rodriguez Lorenc, Karen, Miller, Michelle, Taran, Tetiana, Jerusalem, Guy

“…Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative…”
Get full text

Breast cancer in young women: do BRCA1 or BRCA2 mutations matter? by Fasching, Peter A

“…Additionally, the cancers might be associated with a previous pregnancy or have a pathogenesis that is based on a genetic predisposition; some data even imply…”
Get full text

Pembrolizumab for Early Triple-Negative Breast Cancer by Schmid, Peter, Cortes, Javier, Pusztai, Lajos, McArthur, Heather, Kümmel, Sherko, Bergh, Jonas, Denkert, Carsten, Park, Yeon Hee, Hui, Rina, Harbeck, Nadia, Takahashi, Masato, Foukakis, Theodoros, Fasching, Peter A, Cardoso, Fatima, Untch, Michael, Jia, Liyi, Karantza, Vassiliki, Zhao, Jing, Aktan, Gursel, Dent, Rebecca, O’Shaughnessy, Joyce

“…The addition of pembrolizumab to platinum-based neoadjuvant chemotherapy significantly increased the percentage of patients with a pathological complete…”
Get full text

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment by Fasching, Peter A, Heusinger, Katharina, Haeberle, Lothar, Niklos, Melitta, Hein, Alexander, Bayer, Christian M, Rauh, Claudia, Schulz-Wendtland, Ruediger, Bani, Mayada R, Schrauder, Michael, Kahmann, Laura, Lux, Michael P, Strehl, Johanna D, Hartmann, Arndt, Dimmler, Arno, Beckmann, Matthias W, Wachter, David L

“…The pathological complete response (pCR) after neoadjuvant chemotherapy is a surrogate marker for a favorable prognosis in breast cancer patients. Factors…”
Get full text

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer by Slamon, Dennis J, Neven, Patrick, Chia, Stephen, Fasching, Peter A, De Laurentiis, Michelino, Im, Seock-Ah, Petrakova, Katarina, Bianchi, Giulia V, Esteva, Francisco J, Martín, Miguel, Nusch, Arnd, Sonke, Gabe S, De la Cruz-Merino, Luis, Beck, J. Thaddeus, Pivot, Xavier, Sondhi, Manu, Wang, Yingbo, Chakravartty, Arunava, Rodriguez-Lorenc, Karen, Taran, Tetiana, Jerusalem, Guy

“…An earlier report documented significant improvement in progression-free survival among patients with metastatic breast cancer treated with fulvestrant and a…”
Get full text

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes by VON MINCKWITZ, Gunter, UNTCH, Michael, JACKISCH, Christian, KAUFMANN, Manfred, KONECNY, Gottfried E, DENKERT, Carsten, NEKLJUDOVA, Valentina, MEHTA, Keyur, LOIBL, Sibylle, BLOHMER, Jens- Uwe, COSTA, Serban D, EIDTMANN, Holger, FASCHING, Peter A, GERBER, Bernd, EIERMANN, Wolfgang, HILFRICH, Jörn, HUOBER, Jens

“…The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain. Tumor…”
Get full text

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials by Denkert, Carsten, Seither, Fenja, Schneeweiss, Andreas, Link, Theresa, Blohmer, Jens-Uwe, Just, Marianne, Wimberger, Pauline, Forberger, Almuth, Tesch, Hans, Jackisch, Christian, Schmatloch, Sabine, Reinisch, Mattea, Solomayer, Erich F, Schmitt, Wolfgang D, Hanusch, Claus, Fasching, Peter A, Lübbe, Kristina, Solbach, Christine, Huober, Jens, Rhiem, Kerstin, Marmé, Frederik, Reimer, Toralf, Schmidt, Marcus, Sinn, Bruno V, Janni, Wolfgang, Stickeler, Elmar, Michel, Laura, Stötzer, Oliver, Hahnen, Eric, Furlanetto, Jenny, Seiler, Sabine, Nekljudova, Valentina, Untch, Michael, Loibl, Sibylle

“…The development of anti-HER2 antibody–drug conjugates opens new therapeutic options for patients with breast cancer, including patients with low expression of…”
Get full text

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial by von Minckwitz, Gunter, Prof, Schneeweiss, Andreas, Prof, Loibl, Sibylle, Prof, Salat, Christoph, MD, Denkert, Carsten, Prof, Rezai, Mahdi, Prof, Blohmer, Jens U, Prof, Jackisch, Christian, Prof, Paepke, Stefan, MD, Gerber, Bernd, Prof, Zahm, Dirk M, MD, Kümmel, Sherko, MD, Eidtmann, Holger, MD, Klare, Peter, MD, Huober, Jens, Prof, Costa, Serban, Prof, Tesch, Hans, Prof, Hanusch, Claus, MD, Hilfrich, Jörn, Prof, Khandan, Fariba, MD, Fasching, Peter A, Prof, Sinn, Bruno V, MD, Engels, Knut, MD, Mehta, Keyur, MBA, Nekljudova, Valentina, PhD, Untch, Michael, Prof

“…Summary Background Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist…”
Get full text

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy by Denkert, Carsten, von Minckwitz, Gunter, Darb-Esfahani, Silvia, Lederer, Bianca, Heppner, Barbara I, Weber, Karsten E, Budczies, Jan, Huober, Jens, Klauschen, Frederick, Furlanetto, Jenny, Schmitt, Wolfgang D, Blohmer, Jens-Uwe, Karn, Thomas, Pfitzner, Berit M, Kümmel, Sherko, Engels, Knut, Schneeweiss, Andreas, Hartmann, Arndt, Noske, Aurelia, Fasching, Peter A, Jackisch, Christian, van Mackelenbergh, Marion, Sinn, Peter, Schem, Christian, Hanusch, Claus, Untch, Michael, Loibl, Sibylle

“…Tumour-infiltrating lymphocytes (TILs) are predictive for response to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive breast…”
Get full text

DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer by Teschendorff, Andrew E, Gao, Yang, Jones, Allison, Ruebner, Matthias, Beckmann, Matthias W., Wachter, David L., Fasching, Peter A., Widschwendter, Martin

“…Identifying molecular alterations in normal tissue adjacent to cancer is important for understanding cancer aetiology and designing preventive measures. Here…”
Get full text

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study by Hurvitz, Sara A, Martin, Miguel, Jung, Kyung Hae, Huang, Chiun-Sheng, Harbeck, Nadia, Valero, Vicente, Stroyakovskiy, Daniil, Wildiers, Hans, Campone, Mario, Boileau, Jean-François, Fasching, Peter A, Afenjar, Karen, Spera, Gonzalo, Lopez-Valverde, Vanesa, Song, Chunyan, Trask, Peter, Boulet, Thomas, Sparano, Joseph A, Symmans, W Fraser, Thompson, Alastair M, Slamon, Dennis

“…The KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, trastuzumab plus P (TCH+P) for the…”
Get full text

Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients by RACK, Brigitte, SCHINDLBECK, Christian, FEHM, Tanja, SCHNEEWEISS, Andreas, LICHTENEGGER, Werner, BECKMANN, Matthias W, FRIESE, Klaus, PANTEL, Klaus, JANNI, Wolfgang, JÜCKSTOCK, Julia, ANDERGASSEN, Ulrich, HEPP, Philip, ZWINGERS, Thomas, FRIEDL, Thomas W. P, LORENZ, Ralf, TESCH, Hans, FASCHING, Peter A

“…Circulating tumor cells (CTCs) have been shown to predict reduced survival outcomes in metastatic breast cancer. CTCs were analyzed in 2026 patients with early…”
Get full text

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial by Stevic, Ines, Müller, Volkmar, Weber, Karsten, Fasching, Peter A, Karn, Thomas, Marmé, Frederic, Schem, Christian, Stickeler, Elmar, Denkert, Carsten, van Mackelenbergh, Marion, Salat, Christoph, Schneeweiss, Andreas, Pantel, Klaus, Loibl, Sibylle, Untch, Michael, Schwarzenbach, Heidi

“…The focus of this study is to identify particular microRNA (miRNA) signatures in exosomes derived from plasma of 435 human epidermal growth factor receptor 2…”
Get full text

Going Digital: A Survey on Digitalization and Large-Scale Data Analytics in Healthcare by Tresp, Volker, Marc Overhage, J., Bundschus, Markus, Rabizadeh, Shahrooz, Fasching, Peter A., Yu, Shipeng

“…We provide an overview of the recent trends toward digitalization and large-scale data analytics in healthcare. It is expected that these trends are…”
Get full text

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer by Schmid, Peter, Cortes, Javier, Dent, Rebecca, Pusztai, Lajos, McArthur, Heather, Kümmel, Sherko, Bergh, Jonas, Denkert, Carsten, Park, Yeon Hee, Hui, Rina, Harbeck, Nadia, Takahashi, Masato, Untch, Michael, Fasching, Peter A, Cardoso, Fatima, Andersen, Jay, Patt, Debra, Danso, Michael, Ferreira, Marta, Mouret-Reynier, Marie-Ange, Im, Seock-Ah, Ahn, Jin-Hee, Gion, Maria, Baron-Hay, Sally, Boileau, Jean-François, Ding, Yu, Tryfonidis, Konstantinos, Aktan, Gursel, Karantza, Vassiliki, O’Shaughnessy, Joyce

“…An interim analysis of a randomized trial in triple-negative breast cancer comparing the addition of pembrolizumab to neoadjuvant chemotherapy with…”
Get full text

Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer by Janni, Wolfgang J, Rack, Brigitte, Terstappen, Leon W M M, Pierga, Jean-Yves, Taran, Florin-Andrei, Fehm, Tanja, Hall, Carolyn, de Groot, Marco R, Bidard, François-Clement, Friedl, Thomas W P, Fasching, Peter A, Brucker, Sara Y, Pantel, Klaus, Lucci, Anthony

“…Although unequivocal evidence has shown the prognostic relevance of circulating tumor cells (CTC) in the peripheral blood of patients with metastatic breast…”
Get full text

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer by Ingold Heppner, Barbara, Untch, Michael, Denkert, Carsten, Pfitzner, Berit M, Lederer, Bianca, Schmitt, Wolfgang, Eidtmann, Holger, Fasching, Peter A, Tesch, Hans, Solbach, Christine, Rezai, Mahdi, Zahm, Dirk M, Holms, Frank, Glados, Manfred, Krabisch, Petra, Heck, Esther, Ober, Angelika, Lorenz, Petra, Diebold, Kurt, Habeck, Jörg-Olaf, Loibl, Sibylle

“…We elucidated the value of tumor-infiltrating lymphocytes (TIL) as an independent predictor for pathologic complete response (pCR) rate and as a prognostic…”
Get full text